Results from the Children’s Oncology Group (COG) AML trials showed that benefit from GO at a single dose of 3 mg/m 2 at first induction and then intensification 9 was restricted to paediatric patients ...

Suppressing CD33 stimulates phagocytosis, slows plaque growth. A protective CD33 mutation could be a gain of function that activates phagocytosis. The CD33 receptor acts as a dimer. At the 14th ...

Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I) CD33 splicing single nucleotide polymorphism was evaluated in ...

CD33 is variably expressed on acute myeloid leukemia (AML) blasts and is targeted by gemtuzumab ozogamicin (GO). GO has shown benefit in both adult and pediatric AML trials, yet limited data exist ...

From their perch on the microglial surface, CD33 and TREM2 exact opposing forces on microglial functions, including phagocytosis and inflammatory responses. Now, in a study published in Neuron on July ...

NEW YORK, April 17, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today announced ...

Acute myeloid leukemia (AML) is one of the most common forms of cancer in children and adults. CD33, a protein often expressed on the surface of leukemic cells, has been a long-standing target for AML ...

M2T-CD33 has received orphan drug designation for AML, offering incentives like tax credits and market exclusivity. The M2T platform is a novel immunotherapy approach targeting CD33-positive leukemic ...

A new approach may provide a new path towards treating acute myeloid leukemia (AML) with CAR T cells. A new approach pioneered at the University of Pennsylvania's Abramson Cancer Center may provide a ...

INB-300, a gamma-delta T cell chimeric antigen receptor (CAR) platform, demonstrated the ability to target cancer cells while sparing healthy tissue when both express the CAR-targeted antigen. CAR ...